Creutzfeldt-Jakob DiseaseSymptoms, Doctors, Treatments, Advances & More
Creutzfeldt-Jakob Disease Overview
Learn About Creutzfeldt-Jakob Disease
Creutzfeldt-Jakob disease (CJD) is a form of brain damage that leads to a rapid decrease in movement and loss of mental function.
Transmissible spongiform encephalopathy; vCJD; CJD; Jacob-Creutzfeldt disease
CJD is caused by a protein called a prion. A prion causes normal proteins to fold abnormally. This affects other proteins' ability to function.
CJD is very rare. There are several types. The classic types of CJD are:
Sporadic CJD makes up most cases. It occurs for no known reason. It starts on average at age 65 years.
Familial CJD occurs when a person inherits the abnormal prion from a parent (this form of CJD is rare).
Acquired CJD includes variant CJD (vCJD), the form related to mad cow disease.
- Variant CJD is caused by eating infected meat. The infection that causes the disease in cows is thought to be the same one that causes vCJD in humans.
- Variant CJD causes less than 1% of all CJD cases. It tends to affect younger people. Fewer than 200 people worldwide have had this disease. Almost all cases occurred in England and France.
- Iatrogenic CJD is also an acquired form of the disease. Iatrogenic CJD is sometimes passed through a blood product transfusion, transplant, or contaminated surgical instruments.
CJD may be related to several other diseases caused by prions, including:
- Chronic wasting disease (found in deer)
- Kuru (affected mostly women in New Guinea who ate the brains of dead relatives as part of a funeral ritual)
- Scrapie (found in sheep)
- Other very rare inherited human diseases, such as Gerstmann-Straussler-Scheinker disease and fatal familial insomnia
CJD symptoms may include any of the following:
- Dementia that gets worse quickly over a few weeks or months
- Blurred vision (sometimes)
- Changes in gait (walking)
- Confusion, disorientation
- Hallucinations (seeing or hearing things that aren't there)
- Lack of coordination (for example, stumbling and falling)
- Muscle stiffness, twitching
- Feeling nervous, jumpy
- Personality changes
- Sleepiness
- Sudden jerky movements or seizures
- Trouble speaking
There is no cure for CJD. Different medicines have been tried to slow the disease, but none works well.
The goals of treatment include:
- Provide a safe environment
- Control aggressive or agitated behavior
- Make the person comfortable
- Meet the person's needs
This may require monitoring and assistance in the home or in a care facility. Family counseling may help the family cope with the changes needed for home care.
People with CJD may need help controlling unacceptable or dangerous behaviors. This involves rewarding positive behaviors and ignoring negative behaviors (when it is safe). They may also need help getting oriented to their surroundings. Sometimes, medicines are needed to help control aggression.
It is helpful for people with CJD and their family to seek legal advice early on. Advance directive, power of attorney, and other legal actions can make it easier to make decisions about the care of the person with CJD.
Tsuyoshi Hamaguchi practices practicing medicine in Kanazawa, Japan. Mr. Hamaguchi is rated as an Elite expert by MediFind in the treatment of Creutzfeldt-Jakob Disease. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Creutzfeldt-Jakob Disease, Cerebral Amyloid Angiopathy, Dementia, and Primary Amyloidosis.
Inga Zerr practices practicing medicine in Goettingen, Germany. Ms. Zerr is rated as an Elite expert by MediFind in the treatment of Creutzfeldt-Jakob Disease. She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses Creutzfeldt-Jakob Disease, Dementia, Fatal Familial Insomnia, and Alzheimer's Disease.
Tetsuyuki Kitamoto practices practicing medicine in Japan. Kitamoto is rated as an Elite expert by MediFind in the treatment of Creutzfeldt-Jakob Disease. They are also highly rated in 6 other conditions, according to our data. Their clinical expertise encompasses Gerstmann-Straussler-Scheinker Syndrome, Creutzfeldt-Jakob Disease, Kuru, and Dementia.
The outcome of CJD is very poor. People with sporadic CJD are unable to care for themselves within 6 months or less after symptoms begin.
The disorder is fatal in a short time, usually within 8 months. People who have variant CJD get worse more slowly, but the condition is still fatal. A few people survive for as long as 1 or 2 years. The cause of death is usually infection, heart failure, or respiratory failure.
The course of CJD is:
- Infection with the disease
- Severe malnutrition
- Dementia in most cases
- Loss of ability to interact with others
- Loss of ability to function or care for oneself
- Death
CJD is not a medical emergency. However, early diagnosis and treatment may make the symptoms easier to control, give people time to make advance directives and prepare for the end of life, and give families extra time to come to terms with the condition.
Medical equipment that may be contaminated should be removed from service and disposed of. People known to have CJD should not donate a cornea or other body tissue.
Most countries now have strict guidelines for managing infected cows to avoid passing CJD to humans.
Summary: Synuclein disease, also known as Synucleinopathies, is a general term for a class of degenerative diseases. It mainly includes Parkinson's disease (PD), Dementia with lewy bodies (DLB), Multiple system atrophy (MSA) and so on. The disease is characterized by the abnormal folding of alpha-synuclein (α-syn) in the peripheral and central nervous system, resulting in the production of lewy bodies, lew...
Summary: The goal of this clinical trial is to improve communication among clinicians, patients with memory problems, and their family members. We are testing a way to help clinicians have better conversations to address patients' goals for their healthcare. To do this, we created a simple, short guide called the Jumpstart Guide. The goal of this research study is to show that using this kind of guide is p...
Published Date: July 17, 2025
Published By: Joseph V. Campellone, MD, Department of Neurology, Cooper Medical School at Rowan University, Camden, NJ. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Bosque PJ, Tyler KL. Prions and prion diseases of the central nervous system (transmissible neurodegenerative diseases). In: Blaser MJ, Cohen JI, Holland SM, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 10th ed. Philadelphia, PA: Elsevier; 2026:chap 185.
Tee BL, Geschwind MD. Prion diseases. In: Jankovic J, Mazziotta JC, Pomeroy SL, Newman NJ, eds. Bradley and Daroff's Neurology in Clinical Practice. 8th ed. Philadelphia, PA: Elsevier; 2022:chap 94.
